Topic: phase 3 trial
-
Pfizer: New COVID Shot Quadruples Immune Response
Pfizer and BioNTech's updated mRNA COVID-19 vaccine significantly boosts immune response, quadrupling neutralizing antibodies in vulnerable groups like older adults and those with pre-existing conditions. Federal vaccine eligibility has shifted to primarily include seniors and medically at-risk i...
Read More » -
mRNA Cancer Vaccine Shows 5-Year Protection, Moderna-Merck Data Reveals
A personalized mRNA vaccine combined with standard immunotherapy nearly halved the risk of recurrence or death in high-risk melanoma patients over five years compared to immunotherapy alone. The vaccine is custom-made for each patient using genetic markers from their tumor to train the immune sys...
Read More »